Several studies have examined the association between warfarin sodium use and risk of osteoporotic fractures with conflicting results. Our study addresses this question, for the first time regarding patients attending emergency department (ED).
discourage physicians from prescribing warfarin sodium.
Background
Warfarin sodium is a common anticoagulant used for many indications, particularly in the elderly. It is derived from Coumarin, which is a vitamin K antagonist thus preventing the activation of vitamin K-dependant clotting factors. [1] [2] [3] Vitamin K plays an important role in bone metabolism as osteocalcin, which enhances calcium binding to the hydroxyapatite bone matrix, contains a gammacarboxyglutamate group, which may be inhibited by vitamin K. [4] [5] [6] [7] [8] [9] [10] Several studies have examined the association between warfarin sodium use and risk of osteoporotic fractures but the results are conflicting. [10] [11] [12] [13] [14] [15] [16] [17] Pilon et al conducted a retrospective study on 1523 cases of patients older than 70 and found no statistical association between warfarin use and osteoporotic fractures. 18 The aim of this study was to retrospectively detect whether, as in previous studies, osteoporotic fractures are not associated with the use of warfarin sodium in patients attending an emergency department (ED) with a typical osteoporotic fracture. This is the first study to address this question with an emergency physician perspective.
Method
Rabin medical hospital is a tertiary centre and its ED is the largest in the Middle East, with more than 150,000 annual visits. This retrospective study was performed by review of computerized charts of all independent elderly individuals (>65 years old) who experienced an osteoporotic fracture after minor trauma and attended the ED in the years 2005-2016. An osteoporotic fracture was defined as any one of several typical fractures (femoral neck, vertebra, proximal humerus or distal radius). Those with an osteoporotic fracture were compared with independent gender-matched elderly individuals (>65 years old) attending the same ED but in the internal or surgery wards for reasons other than an osteoporotic fracture.
Patients with fractures not typical of osteoporosis or fractures following major trauma or suspected of being pathologic fractures, patients who used anticoagulants other than warfarin sodium or severely debilitated patients were excluded from the study. Table 2 .
A higher proportion of individuals in the fracture group had a previous diagnosis of osteoporosis and were treated medically for this indication, but the difference between groups was not statistically significant (60 patients (37 per cent) vs. 46 patients (28 per cent), respectively, p=0.125).
More patients in the fracture group were treated with bisphosphonates (34 patients (21 per cent) vs. 20 patients (12 per cent), respectively, p=0.037) ( Table 3 ).
As noted in Table 2 , warfarin sodium was used in 61 individuals (19 per cent) in the entire cohort, 34 in the fracture group and 27 in the non-fracture group, without statistical difference (p=0.324). In addition, there was no association between warfarin sodium use and type of fracture (Table 4) .
Discussion
The main results of this study are that warfarin sodium use is not more prevalent in elderly individuals who experience an osteoporotic fracture and this lack of association persists irrespective of duration of treatment, warfarin sodium dose or effectiveness of treatment. There is conflicting evidence in the literature regarding the role of warfarin sodium in inhibiting bone metabolism and its clinical significance. A meta-analysis that examined observational studies, found that warfarin sodium use was associated with a decreased distal radius, but not spine or hip, bone mass. 11 Studies have found an association between an increased risk of fractures in the spine and ribs in women taking warfarin sodium 12 but not with hip fracture in men and women. 13, 14 A large study in older women showed that there was no association between the use of warfarin sodium and a decrease in bone mineral density or risk of fracture. 15 In that study, use of warfarin sodium was self-reported. A study by Woo and colleagues revealed that during 3.4 years of follow-up, bone mineral density did not differ significantly between those treated and those untreated with warfarin sodium. 16 On the other hand, another study performed in patients with mechanical heart valves treated with warfarin sodium found that treatment was associated with a decrease in bone mineral density in the spine. 17 Because most studies evaluated bone mineral density and not fracture outcome, the association between actual use of warfarin sodium (not just self-reporting) and osteoporotic fractures is highly debated. Pilon et al., showed no statistical significant association between osteoporotic fractures and warfarin sodium use regarding fracture outcome in elderly patients. 18 This study evaluated the association between established osteoporotic fractures and verified use of warfarin sodium in elderly patients attending an ED, in order to aid the emergency physician to consider the risk factors of the patient to have an osteoporotic fracture. As previous studies evaluated the association between use of warfarin sodium and fractures, this is the first study to evaluate the association between established osteoporotic fractures and warfarin sodium use in ED patients. The lack of association between established osteoporotic fractures and warfarin sodium use supports the fact that warfarin sodium probably does not significantly influence bone morphology and its use should not be considered a risk factor for osteoporotic fractures. This lack of association is in accordance with two recent trails. 19, 20 As warfarin sodium is frequently prescribed to elderly individuals who are at risk for osteoporotic fractures, and considering the fact that heparin and low molecular heparin are associated with decreased bone mass, 21 the fact the warfarin use is not associated with fractures is important to a clinician when confronting an ED patient with an osteoporotic fracture.
Limitations
This study has several limitations. First, because data was collected retrospectively and consecutive patients with a diagnosis of osteoporotic fracture were analysed, there is possibly an unpredictable bias; second, the fracture group were slightly older. This may have influenced the rate of use of warfarin sodium between the two groups, although the age difference was small. Third, because we evaluated a cohort of individuals evaluated in the ED, this cohort probably represents the more severe forms of fractures, as less severe fractures were probably treated in clinics outside the ED. It is thus possible that less severe osteoporotic fractures are in fact associated with warfarin sodium use and this study's conclusions should not be generalised to include all osteoporotic fractures. Yet, because fractures evaluated in the ED and particularly hip fractures are the most significant fractures associated with osteoporosis, this lack of association is certainly reassuring. Fourth, there was a difference of gender between the two groups. The reason for this is was the higher prevalence of osteoporosis in female patients. We thought that matching the gender in this case will create a bias on its own when considering a patient attending an ED. Despite all these limitations, the main strengths of this study are the confirmed fractures and actual use of warfarin sodium and the evaluation of INR values in the year prior to the fracture, attesting to the effectiveness of warfarin sodium use.
Conclusion
Warfarin sodium is not associated with osteoporotic fractures in patients attending the ED and the occurrence of an osteoporotic fracture should not discourage the clinician from using warfarin sodium. 
